- Home
- ACCS vs QNME Comparison
ACCS vs QNME Comparison
Compare ACCS & QNME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACCS | QNME |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Integrated Freight & Logistics |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 14.1M |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ACCS | QNME |
|---|---|---|
| Price | $3.61 | $0.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | 14.0K | ★ 627.9K |
| Earning Date | 11-10-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 139.36 | 47.83 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,619,000.00 | $5,850,681.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 111.79 |
| 52 Week Low | $3.21 | $0.26 |
| 52 Week High | $11.34 | $1.40 |
Technical Indicators
Market Signals| Indicator | ACCS | QNME |
|---|---|---|
| Relative Strength Index (RSI) | 35.49 | 37.85 |
| Support Level | $3.21 | $0.28 |
| Resistance Level | $5.11 | $0.43 |
| Average True Range (ATR) | 0.33 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 37.11 | 10.24 |
Price Performance
Historical ComparisonAbout ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About QNME Quanome Technologies Inc. Common Stock
Quanome Technologies Inc operates in the midstream segment of the pharmaceutical industrial ecosystem, operating between upstream pharmaceutical manufacturers and downstream medical end customers. It sources products from multiple manufacturers and suppliers, and distribute them to hospitals, pharmaceutical distributors and other healthcare providers. Its principal product categories include infusion products, foods for special medical purposes, and specialty pharmaceuticals. It operates in one reportable segment serves its customers by providing pharmaceutical products in China. The company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis.